Kyleena

Product Overview

Alternative Name: LNG Contraceptive IUS (LCS), LCS16

Development Status: SRA/WHO PQ Approved

Target: Female

Mode: Hormonal

Delivery Type: Intrauterine

Duration Type: Long-acting

Description: A new low-dose levonorgestrel contraceptive intrauterine systems (LCS), Kleena(R) delivers 16 µg/24h and is effective for 5 years. Kyleena is similar to Mirena, but with a drug content of only 19.5 mg LNG (as opposed to 52mg LNG).

Updated date: May 30, 2018

Vertical Tabs

Status

Project Phase: Post-development

Project Stage: Marketed

Status Details:
  • The U.S. Food and Drug Administration (FDA) approved Kyleena in September 2016.
  • Kyleena will be available in the U.S. in October 2016.
  • In Nov. 2015, Bayer preregistered the product for contraception in the European Union.

Download Product Report